

(43) International Publication Date
17 July 2014 (17.07.2014)(10) International Publication Number
WO 2014/108679 A1

(51) International Patent Classification:

C07D 401/14 (2006.01) **C07D 417/06** (2006.01)
C07D 231/14 (2006.01) **C07D 417/14** (2006.01)
C07D 401/06 (2006.01) **C07D 207/34** (2006.01)
C07D 401/10 (2006.01) **C07D 249/10** (2006.01)
C07D 403/10 (2006.01) **A61P 27/02** (2006.01)
C07D 409/06 (2006.01) **A61K 31/427** (2006.01)
C07D 409/14 (2006.01) **A61K 31/4436** (2006.01)
C07D 413/06 (2006.01) **A61K 31/4025** (2006.01)

(21) International Application Number:

PCT/GB2014/050043

(22) International Filing Date:

8 January 2014 (08.01.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

1300304.1	8 January 2013 (08.01.2013)	GB
61/750,074	8 January 2013 (08.01.2013)	US
61/865,732	14 August 2013 (14.08.2013)	US

(71) Applicant: **KALVISTA PHARMACEUTICALS LIMITED** [GB/GB]; Building 227, Tetricus Science Park, Porton Down, Salisbury SP4 0JQ (GB).(72) Inventors: **ALLAN, Christine Elizabeth**; 18 Ainsley Gardens, BoyattWood, Eastleigh, Hants SO50 4NX (GB). **BATT, Andrzej Roman**; 41 Kent Road, St. Denys, Southampton, Hants SO17 2LJ (GB). **DAVIE, Rebecca Louise**; c/o KalVista Pharmaceuticals Limited, Building 227, Tetricus Science Park, Porton Down, Salisbury SP4 0JQ (GB). **EDWARDS, Hannah Joy**; c/o KalVista Phar-

maceuticals Limited, Building 227, Tetricus Science Park, Porton Down, Salisbury SP4 0JQ (GB). **EVANS, David Michael**; c/o KalVista Pharmaceuticals Limited, Building 227, Tetricus Science Park, Porton Down, Salisbury SP4 0JQ (GB). **PETHEN, Stephen John**; c/o KalVista Pharmaceuticals Limited, Building 227, Tetricus Science Park, Porton Down, Salisbury SP4 0JQ (GB).


(74) Agents: **HALLYBONE, Huw George** et al.; Carpmals & Ransford LLP, One Southampton Row, London WC1B 5HA (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: BENZYLAMINE DERIVATIVES



(57) Abstract: The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R1 to R3, R5 to R9, A, P, V, W, X, Y and Z are as defined herein.



Published:

— *with international search report (Art. 21(3))*